The University of Oxford’s COVID-19 vaccine candidate, developed in partnership with the biotech AstraZeneca, is the third vaccine this week to publicize promising data from its clinical trials. And, in a surprising twist, it appears that a lower dose of the vaccine does a better job at protecting participants from COVID than a higher dose.
In what could prove to be a turning point in the fight against COVID-19, U.S. pharmaceutical giant Pfizer and German biotech company BioNTech announced yesterday that one of their coronavirus vaccines is more than 90% effective at preventing the viral disease, according to new data from its Phase III trial. They are predicting that they will have the requisite safety data for an Emergency Use Authorization from the FDA before the end of the month.
On Tuesday, the FDA announced a new program called Project Patient Voice that aims to provide cancer patients with more information about their treatment options by making patient-reported outcome (PRO) data from clinical trials publicly available.